StocksMedium•4 November 2026•
1 min read
Inovio Upgraded to 'Buy' Following FDA Approval of DNA-Based Voceryq
Key Facts
1Inovio Pharmaceuticals was upgraded from 'Hold' to 'Buy' following the FDA's accelerated approval of its Voceryq (INO-3107) treatment.
2Voceryq is the first DNA medicine to receive FDA approval, validating the company's platform for future immunotherapy approvals.
3Inovio faces competition from Precigen's Papzimeos but offers potential advantages in safety and dosing convenience.
Seeking Alpha upgraded Inovio Pharmaceuticals from 'Hold' to 'Buy' following the FDA's accelerated approval of its Voceryq treatment. Voceryq marks a significant milestone as the first DNA-based medicine to receive FDA approval, validating the company's technology platform for recurrent respiratory papillomatosis.
Inovio Pharmaceuticals closed at $1.66 on November 3, 2026, amid competition from Precigen's Papzimeos, which saw its stock close at $5.25 on the same date. According to Seeking Alpha, Voceryq offers potential advantages in safety and dosing convenience over its rivals, strengthening the commercial outlook for Inovio's immunotherapy pipeline.